Search clinical trials for: LEO 90105 = calcipotriol betamethasone dipropionate

Total 233 results

LEO Pharma
Quintiles, Inc.

Completed

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Japan
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
University of British Columbia

Unknown

Nickel Desensitization Using Topical Therapy

Allergic Contact Dermatitis

Canada
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 90100 in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (LP0113-1123)

Skin and Connective Tissue Diseases

France
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Germany, United Kingdom
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
Xijing Hospital

Completed

Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis

Psoriasis

China
LEO Pharma

Completed

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

Croatia, Germany, Poland, Serbia
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

China
Garlapati Komali

Unknown

Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Oral Lichen Planus

India
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
Jooheung Lee

Completed

Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (TRIANGLE)

Psoriasis Vulgaris

Korea, Republic of
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Psoriasis of Scalp

Canada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
LEO Pharma

Completed

Efficacy and Tolerability of Enstilar® in Daily Practice

Plaque Psoriasis

Germany
LEO Pharma

Completed

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (BODYGUARD)

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis

Psoriasis of Scalp

France, Canada, Belgium, Denmark, Sweden
LEO Pharma

Completed

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Netherlands, Poland, Romania
LEO Pharma

Completed

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Real-life Evaluation of the Daivobet® Gel Applicator (ASAP PSO)

Plaque Psoriasis

France
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Psoriasis Vulgaris

United States
MC2 Therapeutics

Completed

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Vasoconstriction

France
LEO Pharma

Completed

PSOREAL - Managing PSOriasis in the REAL World (PSOREAL)

Psoriasis Vulgaris

United Kingdom, Canada, Sweden
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Psoriasis Vulgaris

Germany
Lipidor AB

Recruiting

A Phase III Study in Subjects With Mild to Moderate Psoriasis. (AKVANO-AKP02)

Mild to Moderate Psoriasis

India
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Psoriasis Vulgaris

Germany
Assiut University

Completed

Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis

Psoriasis Vulgaris | Fractional CO2 Laser

Egypt
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Psoriasis Vulgaris

United States
LEO Pharma

Completed

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

Skin and Connective Tissue Diseases

Germany
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Stable Plaque Psoriasis

China
LEO Pharma

Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Primus Pharmaceuticals
Prosoft Clinical

Completed

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Plaque Psoriasis

United States
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 90100 Foam

Healthy

Japan
GlaxoSmithKline

Completed

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Psoriasis

France
University Hospital Tuebingen

Recruiting

Stress and Fetal Brain Development

Pregnancy

Germany
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada

3

Subscribe